(R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol

We are (R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol CAS:330156-50-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol
CAS.NO:  330156-50-8
Synonyms:
(R)-2,6-Dichloro-3-fluoro-α-methylbenzyl Alcohol
(R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol
(R)-1-(2,6-Dichloro-3-fluorophenyl)ethan-1-ol
(αR)-2,6-Dichloro-3-fluoro-α-methylbenzenemethanol
Benzenemethanol, 2,6-dichloro-3-fluoro-α-methyl-, (αR)-
(R)-1-(2,6-Dichloro-3-fluorophenyl)-ethanol
(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol

Molecular Formula:C8H7Cl2FO
Molecular Weight:  209.045

Physical and Chemical Properties:
Density:1.4±0.1 g/cm3
Boiling point: 747.5±70.0 °C at 760 mmHg
Melting point:41.0 to 45.0 °C
Flash point: 111.8±25.9 °C
Refractive index: 1.547

Specification:
Appearance: Light yellow or yellow solid
Purity:≥98.0%
Water : ≤0.50%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Crizotinib CAS:877399-52-5.

Related News: The chemical compound which is in the process of becoming an API from a raw material is called an intermediate.6-Iodo-1-hexanol acetate Corden Pharma group companies offer contract development and contract manufacturing for advanced pharmaceutical intermediates, APIs, and drug product formulations with more than 1,500 individuals supporting their customers with specialized technologies in all international markets.1,4-Difluoro-2-methyl-5-nitrobenzene On the other hand, the company has many new products in recent years, including Duqiao Base, Yancheng United Chemical and Dezhou United Chemical. These new products are mostly customized products with strong profitability, which has improved the gross profit margin of the industrial business.2-Propyl-1H-imidazole-4,5-dicarboxylic acid Jo Soden, Co-managing Director of Retrogenix, said “We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant’s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.”Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells.